ERBB2 and breast cancer: Figure 4 illustrates the decrease in Bcl-2 expression in aggressive breast cancer subtypes, such as triple negative cases and Her2 negative cases, compared to Luminal A. We observed the same pattern of cytoplasmic Bcl-2 expression among our samples when we classified the Bcl-2 score according to the median score (low = 0 and high > 0).